Medical Science Liaison/Senior Medical Science Liaison - Immunology and Targeted Therapy

Built for This: Deerfield Group expands leadership to advance next phase of growth, harnessing innovation, technology anchored in human expertise. Sep 15, 2026, 08:00 ET New leadership expansion includes industry veterans Brian Rocks, Chief Financial Officer, and Shelby Rauen, Head of Strategy Expanded roles for Dominic Viola, Chief Innovation Officer, Tim Frank, Chief Marketing Officer, and Amanda Sellers, Chief Communications Officer, alongside existing Deerfield leadership Launches Industry Pain Benchmark Survey at FiercePharma Week to uncover operational pain points healthcare marketers and communicators experience PHILADELPHIA, Sept. 15, 2026 /PRNewswire/ - Deerfield Group, a leading, fully integrated marketing, communications, and media partner for healthcare and life sciences companies, today announced a leadership expansion to advance Built for This - the agency's model for its next phase of growth. The company has appointed Brian Rocks as Chief Financial Officer and Shelby Rauen as Head of Strategy, and elevated the roles of Dominic Viola, Chief Innovation Officer, Amanda Sellers, Chief Communications Officer, and Tim Frank, Chief Marketing Officer, who will work alongside existing company leadership organized around Built for This, which pairs senior-level strategy, experience, and relationships with flexible scale and technology to meet every moment. The announcement follows Deerfield's strategic majority investment from Martis Capital to accelerate development of the agency's proprietary solutions for speed to market and return on investment across the brand life cycle. The investment reinforces a founding Deerfield principle: advance and structure the agency to anticipate industry shifts, not react to them. "Deerfield is an agency on the move. We have challenged the status quo from the beginning and are constantly evolving to anticipate and meet our clients' changing needs," said Frank Burrell, Chief Executive Officer, Deerfield Group. "We have always led with innovation, but our core has always been, and always will be, our people. As technology becomes a commodity across the industry, senior-level judgment, experience, and relationships are what set the agency apart." Built for This is Deerfield's approach to an industry-wide plateau on which every agency now runs on largely the same AI and technology stack, and as a result, tools and speed alone no longer set anyone apart. Deerfield's model is built around the alternative: pairing advanced technology with decades of senior-level experience, so that scale never comes at the cost of original thinking, true partnership, or client trust. Deerfield will put Built for This into practice in real time at FiercePharma Week (September 14-17, Philadelphia, Booth #1501), where the agency will collect insights and feedback directly from clients on the key pain points plaguing healthcare marketers and communicators - from budget and timeline pressure to the growing complexity of approvals and channel mix. Those conversations mark the opening phase of a larger industry survey of healthcare marketers and communicators, the Industry Pain Benchmark, with full results to be issued in Q4 2026. Unencumbered by the layers and silos of legacy agency models, Deerfield combines the substance of scale with senior expertise across marketing, finance, innovation, and strategy - veteran leadership charged with organizing the agency for growth while keeping it nimble, fast, and senior-led. Key leadership responsibilities include: * Brian Rocks, Chief Financial Officer: With deep industry experience in finance from Heartbeat, Digitas Health, and Publicis Health, Rocks leads Deerfield's finance function with a mandate to build an agile model to flex resources across the agency as client needs shift - replacing the static staffing structures that slow larger agencies down * Shelby Rauen, Head of Strategy: Previously at AREA 23 and Eversana, Rauen leads Deerfield's strategy practice, organizing it around a more fluid, diversified team model shaped by individual strategists' strengths rather than the industry's traditional brand, medical, and engagement silos, and expanding the discipline beyond promotional work into content, education, and experiences that solve meaningful tensions. * Dominic Viola, Chief Innovation Officer: Viola spearheads the development and integration of emerging technology adoption and digital capabilities across the agency alongside Deerfield's dedicated technology team, with a mandate to ensure new tools and AI capabilities buy back time for senior-level judgment and true client partnership rather than replace it. * Tim Frank, Chief Marketing Officer: Frank leads key accounts to continually evolve how we are serving our teams across growing agency expertise to put client needs first by building a culture of humility, innovation, and agility. * Amanda Sellers, Chief Communications Officer: Sellers oversees external, internal, and client communications to evolve the agency's storytelling and connectivity to each of the agency's audiences. About Deerfield Group Deerfield Group is a fully integrated marketing, media, communications, and technology agency built for the pace and complexity of pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's model pairs senior-level strategy and human judgment with technology. A senior core team stays close with flexible capability to scale as needed across strategy, creative, digital, media, PR, analytics, sales enablement, and print. Built for This - and what's next. Learn more at DeerfieldGroup.com. SOURCE Deerfield Group

Lundbeck and EVERSANA announce strategic partnership to advance ai-powered commercialization. Aug 25, 2026, 07:59 ET Collaboration expands deployment of EVERSANA's AI Agency platform and commercialization capabilities to advance Lundbeck's Focused Innovator strategy and bionic ambitions CHICAGO and DEERFIELD, Ill., Aug. 25, 2026 /PRNewswire/ - Lundbeck, a global pharmaceutical company focused exclusively on brain health, and EVERSANA(R), a leading global provider of commercial services to the life sciences industry, today announced a strategic partnership to advance AI-powered commercialization across Lundbeck's U.S. commercial organization. The collaboration will broaden Lundbeck's use of EVERSANA's AI Agency platform and related commercialization capabilities, creating a scalable framework for accelerating strategy development, content creation, omnichannel engagement and commercial execution. The partnership supports Lundbeck's Focused Innovator strategy and ambition to build bionic capabilities, bringing human expertise and artificial intelligence together to achieve results neither can deliver alone. The companies share a commitment to deploying AI responsibly and at scale while maintaining the compliance, quality, scientific rigor and governance standards required for the life sciences industry to best serve healthcare providers, patients, families and communities. "At Lundbeck, building bionic capabilities is an important part of how we are advancing our Focused Innovator strategy," said Tom Gibbs, EVP and President, Lundbeck U.S. "Our ambition is to bring human expertise and artificial intelligence together to strengthen how we think, decide and execute across our business. Building on the progress we have made with EVERSANA, our expanded collaboration will help us scale bionic capabilities responsibly across our commercial organization, improve the speed and quality of execution and ultimately, help us deliver greater value to our customers and patients while maintaining the high standards that define our business." The announcement follows the successful deployment of EVERSANA's AI-powered capabilities in support of Lundbeck's commercialization activities. Through the initial work, Lundbeck and EVERSANA introduced AI-driven workflows to accelerate strategic planning, content development and commercial execution while maintaining rigorous medical, legal and regulatory review processes. Through the expanded partnership, Lundbeck will scale AI-enabled commercialization capabilities across multiple areas, including marketing, medical communications, market access and media operations. The companies will also explore additional use cases designed to enhance operational performance and commercial excellence. "The future of commercialization will belong to organizations that successfully combine human expertise with AI-driven execution," said Mark Thierer, Chief Executive Officer, EVERSANA. "Lundbeck is advancing innovation and actively implementing new ways of working. Together, we are creating a model that pairs the power of artificial intelligence with deep life sciences expertise to help commercial teams move faster, operate more efficiently and deliver greater impact." Launched in 2025, EVERSANA's AI Agency is an end-to-end AI-powered commercialization platform built specifically for life sciences. Developed in collaboration with Google Cloud, the platform combines agentic AI, advanced automation and human expertise to accelerate the development of strategy, content and omnichannel engagement while supporting compliance and governance requirements unique to the pharmaceutical industry. "What makes this partnership unique is that we're not simply introducing AI tools into existing workflows," said Faruk Capan, Chief Innovation Officer, EVERSANA. "Together, we're implementing an AI-powered operating model designed specifically for life sciences. By combining agentic AI, embedded compliance and human expertise, we can help commercial teams accelerate execution while maintaining the quality and scientific rigor the industry demands." The strategic partnership supports Lundbeck's Focused Innovator strategy and bionic ambitions. By combining AI-powered capabilities with deep industry expertise, Lundbeck is helping shape how the next generation of pharmaceutical commercialization will be designed and delivered. About Lundbeck Lundbeck is a global biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long-term value for our shareholders by making positive contributions to patients, their families and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. Lundbeck US comprises the wholly owned US subsidiaries of H. Lundbeck A/S (HLUNa / HLUNb, HLUNA DC / HLUNB DC) ("Lundbeck"), including Lundbeck LLC and Lundbeck Pharmaceuticals LLC. For additional information, please visit Lundbeck.com/us and connect with us on LinkedIn, Instagram, and X at @LundbeckUS. About EVERSANA(R) EVERSANA(R) is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA(R), visit eversana.com or connect through LinkedIn and X. Media Contact EVERSANA Matt Braun Vice President, Corporate Communications [email protected] SOURCE EVERSANA